Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    November 7, 2024
  • معلومة اضافية
    • Document Number:
      20240368271
    • Appl. No:
      18/683174
    • Application Filed:
      August 18, 2022
    • نبذة مختصرة :
      Currently, more than 60% of the U.S. population is overweight. and close to 40% is obese. Obesity is considered to be an epidemic. Obesity is not just characterized by an increase in body mass. but it also comes with a range of physiological changes. As a result. obese and ovenweight people are at a higher risk for developing life-threatening conditions such as cardiovascular diseases. diabetes and many types of cancers. Herein are methods. compositions and kits for enhancing immune cell mediated cancer treatment in overweight and obese individuals.
    • Claim:
      1. A method for the treatment of cancer in an overweight or obese individual, the method comprising: administering an effective dose of an agent that blocks or inhibits GPR65 activation or decreases GPR65 expression in tumor associated macrophages, wherein tumor associated macrophage in the individual have increased anti-tumor activity after administration of the agent.
    • Claim:
      2. The method of claim 1, wherein the agent is an antibody that selectively binds to and inhibits GPR65 activation.
    • Claim:
      3. The method of claim 2, wherein the antibody selectively binds to an epitope in the first extracellular domain of GPR65.
    • Claim:
      4. The method of claim 1, wherein the agent is a small molecule drug that selectively binds to to and inhibits GPR65.
    • Claim:
      5. The method of claim 1, wherein the agent is an RNAi specific for GPR65.
    • Claim:
      6. The method of claim 4, wherein the RNAi targets a sequence of SEQ ID NO:1-16.
    • Claim:
      7. The method of claim 1, wherein the agent is an anti-sense RNA specific for GPR65.
    • Claim:
      8. The method of claim 1, comprising administering an effective dose of macrophages engineered to be deficient in GPR65 expression when tumor-associated.
    • Claim:
      9. The method claim 1, wherein administration is systemic.
    • Claim:
      10. The method of claim 1, wherein administration is localized to the tumor environment.
    • Claim:
      11. The method of claim 1, wherein the individual has a body mass index (BMI) of ≥25 kg/m2.
    • Claim:
      12. The method of claim 1, wherein the individual has a body mass index (BMI) of ≥25 kg/m2.
    • Claim:
      13. The method of any of claim 1, wherein the cancer is a solid tumor.
    • Claim:
      14. The method of claim 13, wherein the cancer is a carcinoma.
    • Claim:
      15. The method of claim 14, wherein the cancer is a colorectal carcinoma.
    • Claim:
      16. A method for the treatment of cancer in an individual, the method comprising: administering an effective dose of an antibody that selectively binds to an epitope in the first extracellular domain of GPR65 and inhibits GPR65 activation.
    • Claim:
      17. The method of claim 16, wherein the individual has a body mass index (BMI) of <25 kg/m2.
    • Claim:
      18. A composition for use in the methods of any of claim 1.
    • Current International Class:
      07; 61; 61; 12
    • الرقم المعرف:
      edspap.20240368271